Core B (Biorepository/Biostatistics). Core B will service Projects 1, 2, and 3 by providing clinically annotated human glioma tissue and serum samples and biostatistics support to the P01.
In Aim #1 (Biorepository), tissue and sera samples from newly diagnosed glioma patients, recurrent glioma patients an biopsy proven cases of radiation necrosis will be prospectively collected and designated for analysis. This will include the initial and longitudinal collection of sera and tumor tissue for a year following diagnosis. Overall, seven collaborating institutions have committed their support to this aim's biospecimen collections.Sample collection, annotation, storage, and analysis between participating sites will be coordinated using a web based sample tracking tool (GBCWEB) that has been created. In addition, the repository will receive and distribute biospecimen samples from non POl collaborating clinical trials that have already tested a specific molecularly targeted therapeutic (e.g. anti-EGFRvlll vaccination-Dr. Sampson, anti-PDGFR inhibition-Dr. Kesari;RTOG Iressa-Dr. Chakravarti). In collaborative fashion. Projects 2 and 3, Core B will test whether the molecular targets of these therapies can be monitored using microvesicle RNA technology. Finally, using the Biostatics and clinical expertise within the core, the Biorepository will generate appropriately powered patient sample sets for testing clinical hypotheses such as whether serum microvesicle RNA signatures of Temozolamide or bevacizamab chemotherapy be determined radiation necrosis versus recurrent glioma be distinguished using microvesicle RNA microarray analysis or whether serum microvesicle tumor specific mutation detection reflects treatment effect or prognosis.
In Aim #2 (Biostatistics), the Core will provide Biostatistical support (Dr. Messer) to all projects and Core C in validating sensitivity and specificity of assays and in appropriate study design.
Glioma contributes the 2nd largest years of life lost to cancer, affecting a young population. It is highly lethal with low duration of survival after diagnosis. The ability to monitor and tailor therapeutics using a serum microvesicle based approach would be a significant advance.
|Bronisz, Agnieszka; Godlewski, Jakub; Chiocca, E Antonio (2016) Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. Cell Mol Neurobiol 36:361-76|
|Mineo, Marco; Ricklefs, Franz; Rooj, Arun K et al. (2016) The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Rep 15:2500-9|
|Ricklefs, Franz; Mineo, Marco; Rooj, Arun K et al. (2016) Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Cancer Res 76:2876-81|
|Jeong, Sangmoo; Park, Jongmin; Pathania, Divya et al. (2016) Integrated Magneto-Electrochemical Sensor for Exosome Analysis. ACS Nano 10:1802-9|
|van der Vos, Kristan E; Abels, Erik R; Zhang, Xuan et al. (2016) Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol 18:58-69|
|Choudhury, Sourav R; Hudry, Eloise; Maguire, Casey A et al. (2016) Viral vectors for therapy of neurologic diseases. Neuropharmacology :|
|Zappulli, Valentina; Friis, Kristina Pagh; Fitzpatrick, Zachary et al. (2016) Extracellular vesicles and intercellular communication within the nervous system. J Clin Invest 126:1198-207|
|Maas, Sybren L N; Breakefield, Xandra O; Weaver, Alissa M (2016) Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol :|
|Pucci, Ferdinando; Garris, Christopher; Lai, Charles P et al. (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352:242-6|
|Turetsky, Anna; Lee, Kyungheon; Song, Jun et al. (2015) On chip analysis of CNS lymphoma in cerebrospinal fluid. Theranostics 5:796-804|
Showing the most recent 10 out of 191 publications